Participation of women in clinical trials for new drugs approved by the food and drug administration in 2000-2002
- PMID: 19243271
- DOI: 10.1089/jwh.2008.0971
Participation of women in clinical trials for new drugs approved by the food and drug administration in 2000-2002
Abstract
Objective: This study aimed to track the inclusion of women in clinical trials for new drugs approved by the Food and Drug Administration (FDA) between 2000 and 2002 and to evaluate the extent of analyses by sex.
Methods: Data were extracted from FDA reviewers' reports, summaries of clinical trials in New Drug Applications (NDAs), and product labeling and organized into a Microsoft Access database. The information collected includes subject enrollment by sex per clinical phase and sex differences in pharmacokinetics, safety, and efficacy as determined by either sponsors or reviewers.
Results: There were 67 New Molecular Entities (NMEs) approved by the FDA between 2000 and 2002. A total of 397,825 subjects were enrolled in 2,323 clinical trials. If 9 sex-specific NMEs are excluded, 297,697 subjects were enrolled in 1,974 clinical trials. Forty-seven percent of participants were male, 49% were female, and 4% of subjects were not specified. Of the 58 sex-nonspecific products in the study, 71% (41 of 58) of sex analyses were performed either by the sponsor or FDA reviewers. Twenty-five NMEs were found to have sex differences in pharmacokinetics, efficacy or adverse events. However, no recommendation was made to adjust dosage based on sex differences.
Conclusions: The percentages of women and men participating in clinical trials varied by year, phase, and product type. However, the overall participation by women and men was comparable, suggesting an improvement in including more women in clinical trials when compared with the previous FDA study evaluating women's participation from 1995 through 1999. As with the previous study, however, a significant underrepresentation of women in early phase trials and in certain areas, such as cardiovascular products, was observed and continues to be an issue of concern. Lack of appropriate analyses by sex should also be noted as an issue of concern.
Comment in
-
Tracking inclusion of women in clinical studies.J Womens Health (Larchmt). 2009 Mar;18(3):301-2. doi: 10.1089/jwh.2008.1308. J Womens Health (Larchmt). 2009. PMID: 19231989 No abstract available.
Similar articles
-
Tracking inclusion of women in clinical studies.J Womens Health (Larchmt). 2009 Mar;18(3):301-2. doi: 10.1089/jwh.2008.1308. J Womens Health (Larchmt). 2009. PMID: 19231989 No abstract available.
-
Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009.J Womens Health (Larchmt). 2013 Jul;22(7):604-16. doi: 10.1089/jwh.2012.3753. Epub 2013 Jun 14. J Womens Health (Larchmt). 2013. PMID: 23768021 Free PMC article.
-
Increasing participation of women in early phase clinical trials approved by the FDA.Womens Health Issues. 2009 Mar-Apr;19(2):89-93. doi: 10.1016/j.whi.2008.09.009. Womens Health Issues. 2009. PMID: 19272558
-
Gender and Ethnicity of Enrolled Participants in U.S. Food and Drug Administration (FDA) Clinical Trials for Approved Ophthalmological New Molecular Entities.J Natl Med Assoc. 2018 Oct;110(5):473-479. doi: 10.1016/j.jnma.2017.12.004. Epub 2018 Feb 1. J Natl Med Assoc. 2018. PMID: 30129511 Review.
-
Participation of racial/ethnic groups in clinical trials and race-related labeling: a review of new molecular entities approved 1995-1999.J Natl Med Assoc. 2001 Dec;93(12 Suppl):18S-24S. J Natl Med Assoc. 2001. PMID: 11798060 Free PMC article. Review.
Cited by
-
The Importance of Gender-Sensitive Health Care in the Context of Pain, Emergency and Vaccination: A Narrative Review.Int J Environ Res Public Health. 2023 Dec 21;21(1):13. doi: 10.3390/ijerph21010013. Int J Environ Res Public Health. 2023. PMID: 38276801 Free PMC article. Review.
-
A genderful research world: rapid review, design, and pilot study of an interactive platform for curated sex and gender health research resources.Int J Equity Health. 2023 Jun 20;22(1):118. doi: 10.1186/s12939-023-01899-2. Int J Equity Health. 2023. PMID: 37340399 Free PMC article.
-
Sex and Gender Differences in Anticancer Treatment Toxicity: A Call for Revisiting Drug Dosing in Oncology.Endocrinology. 2022 Jun 1;163(6):bqac058. doi: 10.1210/endocr/bqac058. Endocrinology. 2022. PMID: 35560216 Free PMC article. Review.
-
Gender Distribution in Randomized Controlled Trials among Patients with Heart Failure with Reduced Ejection Fraction: A Systematic Review.Glob Heart. 2022 Feb 1;17(1):8. doi: 10.5334/gh.1093. eCollection 2022. Glob Heart. 2022. PMID: 35174049 Free PMC article. No abstract available.
-
Sex-Based Differences in Autologous Cell Therapy Trials in Patients With Acute Myocardial Infarction: Subanalysis of the ACCRUE Database.Front Cardiovasc Med. 2021 May 26;8:664277. doi: 10.3389/fcvm.2021.664277. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34124198 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials